Advertisement

Topics

Search Results for "En Vivo EVP6124 Alzheimer"

13:40 EDT 23rd April 2017 | BioPortfolio

Matching Channels

Cytoplasmic Protein Tau

One of the main pillars of current drug discovery and development activities in the pharmaceutical industry for Alzheimer's disease is prevention of the accumulation of misfolded proteins, i.e. ...

Histone Deacetylase HDAC Inhibitors

Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential anticancer agents for the treatment of solid and hematological malignancies. HDAC inhibition causes acetylated nuclear ...

Nerve growth factor NGF

Nerve growth factor (NGF) is the prototypical member of the family of neurotrophin growth factors that are involved in the growth and survival of nervous tissue. NGF and its receptors, the tyrosine-...

Interleukin 1 IL 1 Receptor IL 1R

Interleukin-1 (IL-1) beta is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production. Current therapy targetin...

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

Matching News

The effects of different familial Alzheimer’s disease mutations on APP processing in vivo

Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis of Alzheimer’s disease (AD). The autosomal dominant form of the disease, familial AD (FAD), may s...

Study using Cubresa SPECT scanner finds potential non-invasive diagnosis for Alzheimer’s

Cubresa’s SPECT scanner was used to determine if a novel molecular label, TRV6001, in development for in vivo imaging of the BChE enzyme present in the brains of Alzheimer’s Disease patients follo...

Medical News Today: Five of the best Alzheimer's blogs

Alzheimer's-related blogs may help to support people with Alzheimer's disease and their caregivers. We take a look at five of the best Alzheimer's blogs.

Five million american seniors now living with alzheimer's

(HealthDay)—Alzheimer's disease claims nearly twice as many American lives annually as it did just 15 years ago, according to the 2017 Alzheimer's Disease Facts and Figures report, published March 7...

JAD's Alzheimer Funding Analyzer now includes Alzheimer's Association grants

(IOS Press) The Journal of Alzheimer's Disease (JAD) is pleased to announce that its Alzheimer's Funding Analyzer (AFA) now includes all Alzheimer's Association (AA) grants in addition to grants from ...

Wandering Poses Unique Risks for Persons Living with Alzheimer's and Dementia

Toledo, Ohio (PRWEB) December 27, 2016 Wandering is a challenging behavior of those suffering with Alzheimer's disease and relat...

Alzheimer’s Research: Where We’ve Failed and What’s To Come

Alzheimer’s disease is a rapidly growing public health crisis. Today an estimated 5.4 million Americans live with the disease and, barring the development of medical breakthroughs to prevent, stop o...

How Much Hope Is There For Alzheimer’s Drugs?

Last night, Alzheimer’s researchers held a celebration over their field’s latest failure. A study of Eli Lilly’s experimental Alzheimer’s drug, solanezumab, failed to show a st...

Matching PubMed Articles

Association of In Vivo 18FAV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.

Previous postmortem studies have long demonstrated that neurofibrillary tangles made of hyperphosphorylated tau proteins are closely associated with Alzheimer disease clinical phenotype and neurodegen...

In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease.

The clinical heterogeneity of Alzheimer's disease is not reflected in the rather diffuse cortical deposition of amyloid-β. We assessed the relationship between clinical symptoms, in vivo tau patholog...

The application of lipidomics to biomarker research and pathomechanisms in Alzheimer's disease.

Alzheimer's disease is the most common cause of dementia. There are still no disease modifying treatments that can cure or slow disease progression. Recently, Alzheimer's disease researchers have atte...

Perspective on calcium and Alzheimer disease.

Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated β-amyloid.

Sensitive detection of cognitive decline over the course of preclinical Alzheimer's disease is critical as the field moves toward secondary prevention trials.

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement